Cell Banking Outsourcing Global Market Report 2024

The cell banking outsourcing market size has grown rapidly in recent years. It will grow from $9.76 billion in 2023 to $11.19 billion in 2024 at a compound annual growth rate (CAGR) of 14.7%. The growth observed in the historical period can be attributed to several factors, including the rise in the prevalence of chronic diseases, increased government initiatives, regulatory support, and guidelines, as well as the expansion of banking services.

The cell banking outsourcing market size is expected to see rapid growth in the next few years. It will grow to $19.51 billion in 2028 at a compound annual growth rate (CAGR) of 14.9%. The projected growth in the forecast period is expected to be driven by factors such as the rising adoption of cellular products, growing demand for monoclonal antibodies, increasing acceptance of stem cell therapies, the expanding geriatric population, and a growing reliance on cell-based therapies. Significant trends anticipated for this period encompass product innovations, technological advancements, investments in research and development, and collaboration between biotech companies and specialized cell banking services.

The increasing prevalence of chronic diseases is poised to drive the expansion of the cell banking outsourcing market in the foreseeable future. Chronic diseases, characterized by long-lasting conditions that develop gradually and persist over an extended period, are on the rise due to various factors such as lifestyle modifications, aging populations, and genetic predispositions. Cell banking outsourcing plays a crucial role in advancing research and development endeavors aimed at combating chronic diseases by offering access to expertise, resources, and infrastructure that may not be available internally. For example, according to the Department of the Treasury, an Australia-based national treasury and financial department, nearly half of Australians of all ages (46.6%) had one or more chronic diseases in 2020-21, with almost one in five (18.6%) experiencing two or more chronic conditions. Therefore, the increasing burden of chronic diseases is fueling the growth of the cell banking outsourcing market.

Prominent companies in the cell banking outsourcing market are dedicated to developing technologically advanced solutions, such as single-cell potency characterization platforms, to deliver precise and comprehensive analysis of individual cell potency. A single-cell potency characterization platform comprises sophisticated technologies or methodologies tailored to evaluate and quantify the potency and functional capabilities of individual cells within a cell population. For instance, in January 2024, Cellply Srl, an Italy-based biotechnology company, introduced VivaCyte, its flagship product and an end-to-end single-cell potency characterization platform. VivaCyte integrates potency analysis and immunophenotyping to streamline cell therapy research and development. This fully automated, standalone platform with single-cell resolution aims to expedite development timelines, reduce costs, and mitigate risks by swiftly characterizing the intricate functionality and mechanism of action of potential cellular immunotherapies. It enables rapid testing of multiple cell therapy candidates against various target tumor cells, providing reproducible immune cell characterization and single-cell functional assessment in a fraction of the time required by conventional analytical tools.

In July 2022, KCAS Bioanalytical & Biomarker Services, a US-based provider of comprehensive bioanalytical services, acquired FlowMetric LLC for an undisclosed sum. Through this acquisition, KCAS intends to bolster its capabilities in supporting cell and gene therapy programs and meet the escalating demands of its clientele by offering additional operational support to effectively address the burgeoning industry needs. FlowMetric LLC, a US-based biotechnology company, specializes in pre-clinical services such as cell sorting, functional analysis of cell signaling, and cell banking outsourcing.

Major companies operating in the cell banking outsourcing market are Labcorp Drug Development, SGS Life Sciences, Lonza Group Ltd., WuXi AppTec, Charles River Laboratories, Sigma-Aldrich Co. Ltd., Covance Inc., Global Stem Inc., LifeCell, Cryoviva India, Sartorius AG, Bio Reliance, CordLife, Reliance Life Sciences, Cryo-Cell International Inc., Toxikon Corp., Cleancells, Clean Biologics, Texcell, PX’Therapeutics SA, Goodwin Biotechnology Inc., Transcell Biolife Pvt Ltd, Perfectus Biomed Limited, BioStorage Technologies Inc.

North America was the largest region in the cell banking outsourcing market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cell banking outsourcing market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the cell banking outsourcing market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Cell banking outsourcing involves contracting external organizations to establish, maintain, and manage repositories of cell lines critical for various applications in the biotechnology and pharmaceutical industries, such as drug discovery and biomanufacturing. This practice ensures that cells are handled, stored, and maintained under standardized conditions, guaranteeing consistency and reliability.

The primary types of cell banking outsourcing encompass master cell banking, working cell banking, and viral cell banking. Master cell banking (MCB) entails a repository of well-characterized cells derived from a single clone, intended to serve as the foundational material for producing therapeutic products such as biologics or cell therapies. This includes various types of cells such as stem cell banking and non-stem cell banking, involving phases such as bank storage, bank characterization and testing, and bank preparation.

The cell banking outsourcing market research report is one of a series of new reports that provides cell banking outsourcing market statistics, including cell banking outsourcing industry global market size, regional shares, competitors with a cell banking outsourcing market share, detailed cell banking outsourcing market segments, market trends and opportunities, and any further data you may need to thrive in the cell banking outsourcing industry. This cell banking outsourcing market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The cell banking outsourcing market includes revenues earned by entities by providing services, such as cell line establishment, cryopreservation, cell line characterization, facilitating the distribution of cell lines, and quality control. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.


This product will be delivered within 3-5 business days.